We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 20, 2009
Last Update Posted: March 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Stempeutics Research Pvt Ltd
This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.

Condition Intervention Phase
Myocardial Infarction Drug: Stem cell Drug: Plasmalyte A Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intravenous ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With st Elevated Acute Myocardial Infarction (Stemi)

Resource links provided by NLM:

Further study details as provided by Stempeutics Research Pvt Ltd:

Primary Outcome Measures:
  • AE and ECG parameters [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Regional myocardial perfusion and infarct size [ Time Frame: 6 months ]

Enrollment: 20
Study Start Date: April 2009
Study Completion Date: August 2012
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: stem cells Drug: Stem cell
IV infusion of stem cells
Placebo Comparator: Placebo Drug: Plasmalyte A
IV infusion


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with STEMI aged between 20 and 70 years, either males or females with non-child bearing potential, after 2 days of successful PCI.
  • Patient has global left ventricular systolic dysfunction with an ejection fraction of <50% and >30%.
  • ECG with sign of acute anterior MI with ST-elevation ≥ 2 mm in at least 2 of the following leads I, AVL, V1-V6, or ECG with sign of acute inferoposterior MI with ST-elevation ≥1 mm on all of the following leads- II, III, V5-V6 or STelevation ≥ 2 mm in at least 2 of the leads.
  • The target lesion located in the proximal section of the left anterior descending, left circumflex or right coronary artery.
  • Patient with acute myocardial infarction within 10 days prior to IP administration.
  • Normal liver and renal function.
  • Able to understand study information provided to him.
  • Able to give voluntary written consent.

Exclusion Criteria:

  • History of acute/chronic inflammatory condition or severe aortic stenosis or insufficiency; severe mitral stenosis or severe mitral insufficiency.
  • Severe co-morbidity associated with a reduction in life expectancy of less than 1 year.
  • Advanced renal dysfunction and creatinine ≥ 2mg%.
  • Advanced hepatic dysfunction.
  • Have clinically serious and/or unstable intercurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00883727

Care Hospital
Hyderabad, Andhra Pradesh, India, 500034
SAL Hospital and Medical Institute
Ahmedabad, Gujarat, India, 380054
MS Ramaiah Memorial Hospital
Bangalore, Karnataka, India, 560054
Bhagawan Mahaveer Jain Heart Centre
Bangalore, Karnataka, India, 5660052
Sponsors and Collaborators
Stempeutics Research Pvt Ltd
Principal Investigator: Sreenivas Kumar, MD, DM Care Hospital, Hyderabad
Principal Investigator: Satya Gupta SAL Hospital, Ahmedabad
Principal Investigator: R Keshava, MD, DM Bhagwan Mahaveer JAin Hospital, Bangalore
Principal Investigator: Prakash VS, MD., DM MS Ramaiah Memorial Hospital, Bangalore
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Stempeutics Research Pvt Ltd
ClinicalTrials.gov Identifier: NCT00883727     History of Changes
Other Study ID Numbers: SRPL/AMI/07-08/001
First Submitted: April 17, 2009
First Posted: April 20, 2009
Last Update Posted: March 5, 2013
Last Verified: March 2013

Keywords provided by Stempeutics Research Pvt Ltd:
mesenchymal stem cells
myocardial infarction

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Plasma-lyte 148
Ophthalmic Solutions
Pharmaceutical Solutions